Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Detection of Triple Negative Breast Cancer Relapse: a Clinical Utility Phase II Trial

NCT06225505 is registered in ClinicalTrials.gov with Institut Curie as lead sponsor.

NCT NCT06225505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06225505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Detection of Triple Negative Breast Cancer Relapse: a Clinical Utility Phase II Trial
Lead sponsor
Institut Curie
Phase
Not applicable
Overall status
Recruiting
Start date
January 5, 2026
Completion date
August 3, 2031
Enrollment
450 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer